Non-Current Assets
Equity Method Investments
Eli Lilly Equity Method Investments increased by 11.2% to $3.12B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.3%, from $3.22B to $3.12B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a -1.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase suggests expansion of strategic partnerships or joint ventures, while a decrease may indicate divestment or impairment of these interests.
Detailed definition
This represents the carrying value of investments in entities where the company exercises significant influence but does...
Peer comparison
Commonly reported by large pharmaceutical firms engaged in collaborative R&D or regional distribution joint ventures.
Metric ID:
equity_method_investmentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.47B | $3.35B | $3.21B | $2.73B | $2.59B | $2.57B | $2.9B | $2.75B | $2.75B | $2.69B | $3.05B | $3.09B | $2.88B | $3.2B | $3.22B | $3.22B | $3.21B | $2.81B | $2.8B | $3.12B |
| QoQ Change | — | -3.6% | -4.1% | -15.1% | -5.1% | -0.5% | +12.7% | -5.2% | -0.2% | -1.9% | +13.4% | +1.1% | -6.8% | +11.2% | +0.5% | +0.2% | -0.5% | -12.4% | -0.2% | +11.2% |
| YoY Change | — | — | — | — | -25.5% | -23.2% | -9.7% | +0.8% | +6.1% | +4.5% | +5.2% | +12.2% | +4.8% | +18.9% | +5.4% | +4.4% | +11.5% | -12.2% | -12.9% | -3.3% |
Range$2.57B – $3.47B
CAGR-2.3%
Avg YoY Growth-0.8%
Median YoY Growth+4.5%
Equity Method Investments at Other Companies
Frequently Asked Questions
- What is Eli Lilly's equity method investments?
- Eli Lilly (LLY) reported equity method investments of $3.12B in Q1 2026.
- How has Eli Lilly's equity method investments changed year-over-year?
- Eli Lilly's equity method investments decreased by 3.3% year-over-year, from $3.22B to $3.12B.
- What is the long-term trend for Eli Lilly's equity method investments?
- Over 5 years (2020 to 2025), Eli Lilly's equity method investments has grown at a -1.1% compound annual growth rate (CAGR), from $2.97B to $2.8B.
- What does equity method investments mean?
- The value of investments in companies where the business holds significant influence but not full control.